comprehensive -WSS

comprehensive

author：Wikipedia 2025-10-02 11:08:28 - browse：2586

Adam's take main illustration — Molly Ferguson/STAT

This week, an encouraging turnaround for Ocular Therapeutix, a chat with Alnylam’s CEO defending changes to the HELIOS-B study and talking up its hypertension treatment, and quick takes on Amylyx and obesity stocks.

A Worst CEO gets some much-needed help

For most of last year, Ocular Therapeutix CEO Antony Mattessich promised shareholders that he was close to nailing down a lucrative pharma partnership that would pay for late-stage clinical trials of the company’s treatments for degenerative eye diseases. The deal never happened. I heard from many Ocular investors who were frustrated and angry about Mattesich’s poor job performance. He ended up earning a spot last year on my worst biopharma CEO list. It was an easy pick.

On Thursday, Ocular announced a meaningful “leadership update.” Mattessich is still the CEO, but let’s just say the company’s board decided to surround him with new executives and retinal experts with proven track records of getting stuff done.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Changes to biosimilar regulatory framework must prioritize patients

WSS

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

CDC's new outbreak response network to include Northeastern

A common UTI test for kids haunts adults as a traumatic 'nightmare'

How medical schools plan to diversify without affirmative action

How medical schools plan to diversify without affirmative action

Second xenotransplant done with gene

knowledge

comprehensive

A Worst CEO gets some much-needed help

entertainment

DIEP, the 'gold standard' of breast reconstruction, is under threat

Biotech lab space demand falls sharply

How to save PrEP access — and even expand it

Food makers to regulators: Ultra

Medicare details structure of new drug price negotiation program

How AI helped researchers track recovery from depression

United colonoscopy coverage change 'may cost lives,' doctors say

Thermo Fisher plant for manufacturing gene therapies to expand

Wildfire smoke exposes gaps in outdoor worker protections

Changes to biosimilar regulatory framework must prioritize patients

hotspot

How medical schools plan to diversify without affirmative action

How Vertex's cystic fibrosis drug is changing patients' lives

Senate HELP committee spars over health care workforce policies

How housing is health care on Long Island

Lasker Awards 2023: Winners in biomedical research

Food makers to regulators: Ultra

knowledge

leisure time

focus

hotspot